Receptor Integral To Or Derived From A Lymphocytic Or Lymphocytic-like Cell (e.g., Nk Cell, Etc.) Patents (Class 424/144.1)
-
Patent number: 10604567Abstract: Disclosed herein are antibodies specific for erythroferrone and assays comprising the antibodies. Also disclosed are methods for using the assays for the diagnosis or monitoring of disease.Type: GrantFiled: March 13, 2018Date of Patent: March 31, 2020Assignee: INTRINSIC LIFESCIENCES LLCInventors: Mark Westerman, Huiling Han, Vaughn Ostland
-
Patent number: 10590195Abstract: The present disclosure relates to recombinant fusion proteins, such as human antibody-based molecules called Vaccibodies, which are able to trigger both a T cell- and B cell immune response. The present disclosure also relates to a method of treating a cancer or an infectious disease by means of these specific fusion proteins.Type: GrantFiled: June 24, 2011Date of Patent: March 17, 2020Assignee: VACCIBODY ASInventors: Pier Adelchi Ruffini, Bjarne Bogen, Agnete Brunsvik Fredriksen
-
Patent number: 10519242Abstract: The present invention provides methods and compositions comprising a heterodimeric antibody comprising a first monomer comprising a first variant heavy chain constant region and an anti-CD4 binding moiety. The heterodimeric antibody also comprises a second monomer comprising: a second variant heavy chain constant region and an anti-CD25 binding moiety. In some cases, the pIs of the first and second variant heavy chain constant regions are at least 0.5 logs apart.Type: GrantFiled: March 14, 2014Date of Patent: December 31, 2019Assignee: Xencor, Inc.Inventors: Seung Chu, Matthew Bernett, Dilki Wickramarachchi, John Desjarlais
-
Patent number: 10512687Abstract: The disclosed compositions and methods relate to an immunogenic composition that, in certain aspects, comprise cationic liposomes; a mixture of toll like receptor 3 (TLR3) and toll like receptor 9 (TLR9) ligands; and a cellular adhesion agent, and methods of using such compositions. In certain aspects, disclosed compositions are administered to a mammal to induce a non-specific innate immune response at mucosal surfaces. In further aspects, disclosed compositions are administered to a mammal in conjunction with an antigen to enhance the immune response of the mammal to the antigen.Type: GrantFiled: March 31, 2017Date of Patent: December 24, 2019Assignees: Colorado State University Research Foundation, The Regents of the University of Colorado, a body corporateInventors: Steven Dow, Michael R. Lappin, William H. Wheat, Lyndah Chow, Daniel P. Regan, Thomas J. Anchordoquy
-
Patent number: 10509033Abstract: Provided are a method for diagnosing chronic inflammatory demyelinating polyneuropathy (CIDP), in particular, a diagnostic method for specifically diagnosing a group having a specific pathophysiology among CIDPs, and a kit and a biomarker for use in such a diagnosis. The diagnostic method for diagnosing CIDP of the present invention includes a step of measuring an anti-neurofascin 155 antibody contained in a sample.Type: GrantFiled: January 20, 2016Date of Patent: December 17, 2019Assignee: Kyushu University, National University CorporationInventors: Junichi Kira, Nobutoshi Kawamura, Ryo Yamasaki, Dai Matsuse, Hidenori Ogata
-
Patent number: 10466325Abstract: The disclosure relates to a method for determining a sequence information element of a magnetic resonance sequence, a computer program product and an evaluation unit for performing such a method, and also a magnetic resonance device having such an evaluation unit. The method includes a determination of the sequence information element based on at least one pattern of the magnetic resonance sequence.Type: GrantFiled: July 24, 2017Date of Patent: November 5, 2019Assignee: Siemens Healthcare GmbHInventors: Andreas Greiser, David Grodzki, Daniel Nico Splitthoff
-
Patent number: 10458986Abstract: The invention relates to senescent cell biomarkers and the uses thereof. The invention also extends to methods and kits for detecting senescence, and drug conjugates and pharmaceutical compositions for killing senescent cells.Type: GrantFiled: May 20, 2015Date of Patent: October 29, 2019Assignee: UNIVERSITY OF LEICESTERInventor: Salvador Macip
-
Patent number: 10444241Abstract: The application provides methods of diagnosis, prognosis, prophylasxis and treatment of CD30+ cancers.Type: GrantFiled: February 8, 2013Date of Patent: October 15, 2019Assignee: SEATTLE GENETICS, INC.Inventors: Tina Albertson, Maria L. Smith
-
Patent number: 10435475Abstract: A method of treating an inflammatory bowel disease is provided. The method comprises administration of an antibody polypeptide that specifically binds a novel epitope of human CD40. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides may be fusions of a domain antibody (dAb) comprising a single VL or VH domain and an Fc domain.Type: GrantFiled: March 9, 2015Date of Patent: October 8, 2019Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Marek Honczarenko, Vaishali Shah, Xiaoni Liu, Wendy L. Trigona, Rong Shi, Suzanne J. Suchard, Karen D. Price, Linda M. Gustavson
-
Patent number: 10420846Abstract: A bifunctional polypeptide comprising a specific binding partner for a peptide-MHC epitope, such as an antibody or T cell receptor, and an immune effector, such as an antibody or a cytokine, the immune effector part being linked to the N-terminus of the peptide-MHC binding part.Type: GrantFiled: April 8, 2019Date of Patent: September 24, 2019Assignee: Immunocore LimitedInventors: Bent Karsten Jakobsen, Annelise Brigitte Vuidepot, Yi Li
-
Patent number: 10420751Abstract: The present invention relates to the field of inflammatory bowel disease. In one aspect, the present invention provides methods for treating inflammatory bowel disease in a patient comprising administering to the patient a therapeutically effective amount of a stem cell mobilizer and an immunosuppressive agent. In particular embodiments, the present invention provides a method for treating inflammatory bowel disease in a patient comprising administering to the patient a therapeutically effective amount of an agent that mobilizes CD34+ and/or CD133+ stem cells and a low dose of an immunosuppressive agent.Type: GrantFiled: July 31, 2015Date of Patent: September 24, 2019Assignee: MedRegen, LLCInventors: Zhaoli Sun, Xuhang Li
-
Patent number: 10407513Abstract: A multivalent antibody fusion protein which comprises an immunoglobulin moiety, for example a Fab or Fab? fragment, with a first specificity for an antigen of interest, and further comprises two single domain antibodies (dAb) with specificity for a second antigen of interest, wherein the two single domain antibodies are linked by a disulfide bond. There is also provided particular dual specificity antibody fusion proteins comprising a Fab or Fab? fragment and one or more single domain antibodies which may be stabilized by a disulfide bond therebetween.Type: GrantFiled: September 25, 2009Date of Patent: September 10, 2019Assignee: UCB BIOPHARMA SPRLInventors: Ralph Adams, Laura Hancock, Sam Philip Heywood
-
Patent number: 10408820Abstract: The application describes an assay for the identification of small molecule modulators of integrin CD11b/CD18 and small molecules capable of modulating activity of this receptor. Such compounds may be used in certain embodiments for treating a disease or condition selected from inflammation, immune-related disorders, cancer, ischemia-reperfusion injury, stroke, neointimal thickening associated with vascular injury, bullous pemphigoid, neonatal obstructive nephropathy, and cardiovascular disease, or in other embodiments for the treatment of a disease or condition selected from immune deficiency, acquired immune deficiency syndrome (AIDS), myeloperoxidase deficiency, Wiskott-Aldrich syndrome, chronic granulomatous disease, hyper-IgM syndromes, leukocyte adhesion deficiency, Chediak-Higashi syndrome, and severe combined immunodeficiency.Type: GrantFiled: June 20, 2014Date of Patent: September 10, 2019Assignee: THE GENERAL HOSPITAL CORPORATIONInventors: Vineet Gupta, M. Amin Arnaout
-
Patent number: 10400043Abstract: The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-CD20 antibody and chemotherapy. Particular embodiments include the administration of anti-CD20 antibody in combination with chemotherapy comprising CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) and/or in combination with a transplantation regimen.Type: GrantFiled: December 28, 2017Date of Patent: September 3, 2019Assignee: Biogen, Inc.Inventors: Christine A. White, Antonio J. Grillo-Lopez
-
Patent number: 10383917Abstract: Provided is an agent for the treatment of an autoimmune disease, the agent comprising C1q/TNF-related protein 3 (CTRP3), and a method for the treatment of an autoimmune disease, the method comprising: administering an agent, which comprises CTRPb3 for the treatment of an autoimmune disease, to a subject in need of a treatment of an autoimmune disease.Type: GrantFiled: November 14, 2014Date of Patent: August 20, 2019Assignee: TOKYO UNIVERSITY OF SCIENCE FOUNDATIONInventors: Yoichiro Iwakura, Masanori Murayama
-
Patent number: 10350242Abstract: The present invention includes methods for handling live cell compositions in non-nutritive buffer. The cells in the compositions maintain their identity and functional characteristics after being stored in non-nutrititive media up to about 72 hours. The storage method enables the cells to be manufactured at a processing facility and shipped to a point of care site. The invention also includes compositions that have been stored in non-nutritive buffer at storage temperatures while maintaining the functional characteristics.Type: GrantFiled: May 2, 2012Date of Patent: July 16, 2019Assignee: IMMUNOVATIVE THERAPIES LTD.Inventor: Michael Har-Noy
-
Patent number: 10336829Abstract: Provided are compounds having the Formula I: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and their use in the intracellular delivery of antibodies.Type: GrantFiled: October 20, 2016Date of Patent: July 2, 2019Assignee: Sorrento Therapeutics, Inc.Inventors: Yanwen Fu, Gunnar Jörg Floris Kaufmann, Heehyoung Lee, Ingale Sampat Lalaso
-
Patent number: 10316085Abstract: The present invention relates in part to the discovery of genes that are deregulated in cancer stem cells (e.g., melanoma stem cells). In some aspects, methods for treating individuals having melanoma are provided; the methods involve modulating (e.g., inducing, inhibiting, etc.) the activity of the cancer stem cell associated genes. In other aspects, cell surface genes that are upregulated in melanoma stem cells are targeted for the selective isolation, detection, and killing of cancer stem cells in melanoma. Other aspects of the invention relate to reagents, arrays, compositions, and kits that are useful for diagnosing and treating melanoma.Type: GrantFiled: September 28, 2015Date of Patent: June 11, 2019Assignee: Children's Medical Center CorporationInventors: Markus H. Frank, Natasha Y. Frank
-
Patent number: 10316095Abstract: Formulations of anti-VLA-1 antibodies are described.Type: GrantFiled: February 14, 2013Date of Patent: June 11, 2019Assignee: Santarus, Inc.Inventors: Adam Jeremy Fowler, Craig Michael Bowe, Wayne Curtis Yount, Nathan Jeremy Cobb, Timothy Martin Kelly
-
Patent number: 10293059Abstract: This invention is directed to a vector which comprises a promoter operably linked to a nucleic acid sequence encoding a therapeutic gene that blocks allergic reactions. The invention is also directed to a composition comprising the vector and method of using the vector to reduce or inhibit an immune response or allergic reaction to an allergen in a mammal.Type: GrantFiled: April 11, 2016Date of Patent: May 21, 2019Assignee: CORNELL UNIVERSITYInventors: Ronald G. Crystal, Odelya E. Pagovich, Maria J. Chiuchiolo
-
Patent number: 10287356Abstract: The invention provides FGFR3 antibodies, and compositions comprising and methods of using these antibodies.Type: GrantFiled: November 18, 2016Date of Patent: May 14, 2019Assignee: Genentech, Inc.Inventors: Avi Ashkenazi, Jing Qing, Christian Wiesmann, Yan Wu
-
Patent number: 10280208Abstract: Provided are methods of treating an HHLA2-bearing tumor in a subject with a fusion protein comprising an IgV-like domain of a TMIGD2 sufficient to treat the HHLA2-bearing tumor. A fusion protein comprising an IgV-like domain of a TMIGD2 and related compositions and encoding nucleic acids are also provided.Type: GrantFiled: April 24, 2015Date of Patent: May 7, 2019Assignee: Albert Einstein College of MedicineInventors: Xingxing Zang, Jordan M. Chinai, Murali Janakiram, Steven C. Almo, Andras Fiser
-
Patent number: 10253095Abstract: Compositions comprising anti-KIR antibodies and one or more secondary anti-cancer agents or anti-viral agents and methods of using such combinations (as combination compositions or in separate administration protocols) in the treatment of cancers (e.g., lung cancer) or viral infection (e.g., HIV or HCV infection) are provided.Type: GrantFiled: July 15, 2011Date of Patent: April 9, 2019Assignees: INNATE PHARMA S.A.S., NOVO NORDISK A/SInventors: Francois Romagne, Peter Andreas Nicolai Reumert Wagtmann, Joakim Glamann
-
Patent number: 10246510Abstract: The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.Type: GrantFiled: September 17, 2013Date of Patent: April 2, 2019Assignee: INNATE PHARMAInventors: Laurent Gauthier, Benjamin Rossi, Hélène Sicard, Carine Paturel
-
Patent number: 10245327Abstract: The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising any one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 178, a fragment of any one sequence of SEQ ID NO: 2 to SEQ ID NO: 178, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.Type: GrantFiled: December 9, 2016Date of Patent: April 2, 2019Assignee: GemVax & KAEL Co., Ltd.Inventor: Sang Jae Kim
-
Patent number: 10196616Abstract: An altered avian NDV that contains the coding sequence of avian interleukin-4 (IL-4), or a portion thereof, in the reverse orientation suppresses in-ovo IL-4 production via RNAi when administered to embryonic birds. An immunogenic composition containing this altered NDV is included in this invention. The altered avian NDV can, optionally contain a polynucleotide encoding a heterologous antigen from a heterologous avian pathogen and can produce said heterologous antigen in-ovo.Type: GrantFiled: February 7, 2018Date of Patent: February 5, 2019Assignees: The United States of America, as represented by the Secretary of Agriculture, University of Georgia Research Foundation, Inc.Inventors: Claudio L. Afonso, Valerie C. Marcano, Nany Stivalis Cardenas Garcia, Qingzhong Yu, Tonya L. Taylor
-
Patent number: 10189906Abstract: The invention relates to antibodies or antibody fragments that bind CD269 (BCMA), thereby disrupting the interaction between CD269 and its native ligands (BAFF and APRIL), and their use in the treatment of plasma cell-mediated diseases such as multiple myeloma and autoimmune diseases.Type: GrantFiled: November 1, 2013Date of Patent: January 29, 2019Assignee: MAX-DELRÜCK-CENTRUM FÜR MOLEKULARE MEDIZINInventors: Martin Lipp, Felix Oden, Uta Höpken, Gerd Müller, Oliver Daumke, Stephen Marino, Daniel Olal
-
Patent number: 10174124Abstract: The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.Type: GrantFiled: December 17, 2014Date of Patent: January 8, 2019Assignee: Genentech, Inc.Inventors: Xiaocheng Chen, Mark S. Dennis, Allen J. Ebens, Jr., Robert F. Kelley, Mary A. Mathieu, Liping L. Sun
-
Patent number: 10106607Abstract: The present invention discloses caninized antibodies with specific properties. The present invention also discloses caninized murine antibodies againstcanine PD-1 that have a high binding affinity for canine PD-1. The invention further discloses the use of the caninized antibodies of the present invention in the treatment of cancer in dogs.Type: GrantFiled: December 19, 2014Date of Patent: October 23, 2018Assignee: Intervet Inc.Inventors: Mohamad Morsey, Yuanzheng Zhang, Ian Tarpey
-
Patent number: 10086046Abstract: The present invention relates to an agent for the treatment and/or prophylaxis of an autoimmune disease, an agent for the formation of regulatory T cells (TReg) in an organism and various methods in which the agents according to the invention are used.Type: GrantFiled: February 22, 2017Date of Patent: October 2, 2018Assignee: AiCuris GmbH & Co. KGInventors: Daniela Paulsen, Nina Brunner, Dorothy Bray
-
Patent number: 10086042Abstract: The present invention relates to, inter alia, compositions and methods, including chimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity. In part, the invention provides, in various embodiments, fusions of extracellular domains of transmembrane proteins that can have stimulatory or inhibitory effects.Type: GrantFiled: November 6, 2017Date of Patent: October 2, 2018Assignee: Heat Biologics, Inc.Inventors: Taylor Schreiber, George Fromm, Suresh De Silva, Neal Schilling
-
Patent number: 10077312Abstract: The present invention relates to bispecific constructs that specifically bind to immune effector cells and, simultaneously, to IL23R-carrying target cells, as well as nucleic acids, vectors, host cells, pharmaceutical compositions, and methods of production and use thereof, including such bispecific constructs for use in treating inflammatory and/or autoimmune diseases and/or cancer.Type: GrantFiled: May 12, 2014Date of Patent: September 18, 2018Assignee: Numab Therapeutics AGInventors: David Urech, Tea Gunde, Sebastian Meyer
-
Patent number: 10034939Abstract: In some embodiments, the methods involve the use of a combination of at least two of the following: an inhibitor of indoleamine-2,3-dioxygenase (IDO), an inhibitor of the PD-L1/PD-1 pathway, an inhibitor of CTLA-4, an inhibitor of CD25, or IL-7. The inventors particularly observed a major synergistic effect of combining anti-CTLA-4 with either an IDO inhibitor, with anti-PD-L1 mAb, or with CD-25 depletion. Such combinations have been found to demonstrate a synergistic effect in treating cancer and tumors, for example by reducing tumor size, increasing the percentage of antigen-specific T cells, and increasing T cell function.Type: GrantFiled: October 25, 2013Date of Patent: July 31, 2018Assignee: The University of ChicagoInventors: Thomas F. Gajewski, Stefani Spranger, Michael Leung
-
Patent number: 10016458Abstract: The invention provides, inter alia, methods for treating vascular deficiencies, including those in diabetic subjects, by transplanting endothelial progenitor cells with transiently reduced p53 expression.Type: GrantFiled: March 11, 2013Date of Patent: July 10, 2018Assignee: Baystate Health, Inc.Inventor: Sabyasachi Sen
-
Patent number: 10000545Abstract: The present invention concerns the use of an inhibitor of an interaction between type IV pilus-associated protein and CD147 for preventing or treating meningoccal bacteraemia and/or infection. The present invention also relates to the combined use of such inhibitor and of an anti-bacterial compound, such as one used to prevent or treat a meningococcal infection. The invention also relates to a method for the prevention and/or treatment of meningococcal bacteraemia and/or infection, and to a method for screening inhibitors of the interaction between type IV pilus-associated protein and CD147.Type: GrantFiled: July 15, 2013Date of Patent: June 19, 2018Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE PARIS DESCARTESInventors: Xavier Nassif, Sandrine Bourdoulous, Olivier Join-Lambert
-
Patent number: 9982023Abstract: Ligand-specific HVEM variants, compositions comprising such variants, and methods of treating inflammatory diseases comprising administering such variants, are provided.Type: GrantFiled: November 15, 2012Date of Patent: May 29, 2018Assignee: Sanford-Burnham Medical Research InstituteInventors: Carl F. Ware, John Sedy
-
Patent number: 9963508Abstract: In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.Type: GrantFiled: October 20, 2014Date of Patent: May 8, 2018Assignees: AMGEN FREMONT INC., PFIZER INC.Inventors: Douglas Charles Hanson, Mark Joseph Neveu, Eileen Elliott Mueller, Jeffrey Herbert Hanke, Steven Christopher Gilman, C. Geoffrey Davis, Jose Ramon Corvalan
-
Patent number: 9963497Abstract: The present disclosure relates to a method for the treatment of a non-pathogen associated inflammatory disorders in a subject in need thereof, comprising administering to said subject an isolated peptide which specifically binds to an amino acid sequence within the dimer interface of a T cell costimulatory pathway member, particularly the T cell costimulatory pathway members CD28 and CTLA4. The present disclosure also relates to pharmaceutical compositions comprising the isolated peptide and to use of the peptide in treating of a non-pathogen associated inflammatory disorders.Type: GrantFiled: December 7, 2014Date of Patent: May 8, 2018Assignees: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD, ATOX BIO LTD.Inventors: Raymond Kaempfer, Anat Shirvan, Gila Arad
-
Patent number: 9950035Abstract: Methods for making non-immunogenic anti-inflammatory cytokine compositions, comprising (a) obtaining a liquid comprising cytokine producing cells from a mammalian donor; (b) contacting the liquid with a solid extraction material to generate a composition rich in interleukin-1 receptor antagonist; and performing one or both of (i) removing cells from the composition and (ii) freezing the composition. The compositions comprise two or more of IL1-ra, sTNF-R1, sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-?1, and sIL-1RII, Compositions may also contain white blood cells and platelets.Type: GrantFiled: March 15, 2013Date of Patent: April 24, 2018Assignee: Biomet Biologics, LLCInventors: Jeffrey R. Binder, Joel C. Higgins, Michael D. Leach, Krista O'Shaughnessey, Jennifer E. Woodell-May
-
Patent number: 9932402Abstract: Methods of treatment to suppress an immune response are provided. The method comprises administering to a subject in need of treatment a naked blocking antibody that binds selectively iNKT cells in an amount effective to suppress the subject's iNKT cell function. Compositions comprising, an isolated, humanized antibody that binds selectively iNKT cells are also provided.Type: GrantFiled: October 26, 2012Date of Patent: April 3, 2018Assignee: NKT Therapeutics Inc.Inventors: Alemseged Truneh, Francis Joseph Carr, Timothy David Jones, James P. Gregson
-
Patent number: 9913830Abstract: The present invention provides nanoparticle-coupled tolerogenic Treg cell therapy for treatment of immune and/or autoimmune disorders. In certain specific embodiments, the present invention can be used in the prevention and/or treatment of autoimmune diseases including, but not limited to, type 1 diabetes, lupus erythematosus (SLE), multiple sclerosis (MS), inflammatory bowel disease (IBD), rheumatoid arthritis, oophoritis, and autoimmune pathology associated with Graft versus Host Disease (GvHD) following hematopoietic stem cell transplantation.Type: GrantFiled: September 10, 2012Date of Patent: March 13, 2018Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATEDInventors: Todd M. Brusko, Benjamin G. Keselowsky, Judit Cserny
-
Patent number: 9880179Abstract: Provided herein are several methods for selecting agents that bind to transmembrane receptors in a conformationally-selective way. In some embodiments, the method may comprise producing: a transmembrane receptor in an active conformation; and said transmembrane receptor in an inactive conformation and using cell sorting to select, from a population of cells comprising a library of cell surface-tethered extracellular capture agents, cells that are specifically bound to either the transmembrane receptor in its active conformation or the transmembrane receptor in its inactive conformation, but not both. In other embodiments, the method may comprise: contacting a GPCR with a population of cells that comprise a library of surface-tethered extracellular proteins; labeling the cell population with a conformationally-specific binding agent, e.g., a G-protein or mimetic thereof; and using cell sorting to select from the cell population cells that bind to the agent.Type: GrantFiled: February 5, 2014Date of Patent: January 30, 2018Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Aaron Michael Ring, Aashish Manglik, Andrew Kruse, Brian Kobilka
-
Patent number: 9867832Abstract: The present invention relates to new medical use of (tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholine-4-yl)methyl-1H-indol-7-yl]amine, and more particularly, to a pharmaceutical composition containing the compound as an active ingredient, which is used for inhibiting an immune response, and/or for inducing differentiation into regulator T cells from undifferentiated T cells and/or promoting proliferation of regulator T cells.Type: GrantFiled: March 25, 2014Date of Patent: January 16, 2018Assignee: LG CHEM, LTD.Inventors: Seok Goo Cho, Na Youn Kim, Eun Jung Kim, Keon Il Im, Jung Yeon Lim, Eun Joo Jeon
-
Patent number: 9868961Abstract: The present invention provides compositions and methods for effectuating the localized expression of anti-CTLA-4 antibody proximal to a target tissue in a patient.Type: GrantFiled: March 30, 2007Date of Patent: January 16, 2018Assignee: The Regents of the University of CaliforniaInventors: James Allison, Michael Curran
-
Patent number: 9840559Abstract: The present disclosure relates to proteins that bind to CD83 and uses thereof, for example, in therapy, prophylaxis, diagnosis, or prognosis.Type: GrantFiled: January 31, 2014Date of Patent: December 12, 2017Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE UNIVERSITY OF QUEENSLAND, DENDROCYTE BIOTECH PTY LTDInventors: Therese Ann Seldon, David John Munster, Derek Nigel John Hart, Martina Louise Jones, Trent Phillip Munro, Stephen Michael Mahler, Eunice Yu Zhou, James D. Marks
-
Patent number: 9801929Abstract: An object of the present invention is to provide a drug and a method for effectively inducing donor-specific immune tolerance in a recipient in transplantation therapy. A complex of an siRNA for a costimulatory factor and schizophyllan is delivered to a Dectin-1 expressing cell which specifically recognizes schizophyllan to regulate the function of the Dectin-1 expressing cell, and therefore can induce immunosuppression effect as well as induce immune tolerance effectively.Type: GrantFiled: July 13, 2012Date of Patent: October 31, 2017Assignee: Napajen Pharma, Inc.Inventors: Ko Rii, Kazuo Sakurai, Masakazu Kobayashi, Hironori Ando, Sadaharu Higuchi, Shiro Takahara
-
Patent number: 9790278Abstract: Antibodies, chimeric antigen receptors, and bispecific T-cell engagers having specificity for B7-H6 and methods for using the same in the diagnosis and treatment of disorders associated with B7-H6 expression are provided.Type: GrantFiled: May 7, 2013Date of Patent: October 17, 2017Assignee: THE TRUSTEES OF DARTMOUTH COLLEGEInventors: Charles L. Sentman, Tong Zhang
-
Patent number: 9790275Abstract: The invention relates to the field of molecular medicine. In particular, it relates to compositions and methods to enhance the clearance of aberrant cells, e.g. cancer cells or virus-infected cells, by the host's immune system. Provided is a composition comprising (i) a therapeutic compound that can trigger a host's immune effector cells against an aberrant cell, such as a therapeutic antibody, and (ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRPalpha.Type: GrantFiled: October 28, 2016Date of Patent: October 17, 2017Assignee: Stichting Sanquin BloedvoorzieningInventor: Timo Kars Van Den Berg
-
Patent number: 9790274Abstract: Embodiments of the invention provide high affinity recombinant EpCAM-binding antibodies. Methods of using a such antibodies as imaging agents, diagnostics and therapeutics are also provided. Dual-nuclear and fluorescently labeled or singly fluorescently labeled contrast agents promise the advantage of molecularly-guided surgical resection via surgical field near-infrared fluorescence (NIRF) imaging following (in the case of dual labeled agents) nuclear imaging for general localization. Currently, nodal staging of most cancers is performed following lymph node (LN) biopsy and dissection for subsequent pathological examination.Type: GrantFiled: March 12, 2014Date of Patent: October 17, 2017Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Barrett R. Harvey, Kenneth L. Pinkston, Ali Azhdarina, Eva M. Sevick-Muraca
-
Patent number: 9757473Abstract: A cell-penetrating peptide, a conjugate of the cell-penetrating peptide with an anticancer agent, and a composition comprising the conjugate is described. An effective means for transferring a cancer-specific anticancer agent can be provided by using the cell-penetrating peptide. More particularly, by preparing the conjugate of the present invention wherein the cell-penetrating peptide and the anticancer agent are combined, the application concentration of a conventional anticancer agent can be reduced and cancer specificity can be provided, and thus an effect of reducing side effects during the treatment process can be obtained.Type: GrantFiled: July 11, 2014Date of Patent: September 12, 2017Assignee: GemVax & KAEL Co., Ltd.Inventor: Sang Jae Kim